Is polycythemia vera a clonal marrow disorder usually driven by JAK2 mutation?

Polycythemia vera (PV) is a primary erythrocytosis in which distinguishing a clonal marrow neoplasm from secondary red-cell elevation has direct diagnostic implications. The claim is well supported.

Clinical and diagnostic evidence

• PV is a clonal, BCR::ABL1-negative myeloproliferative neoplasm with marrow panmyelosis—not simply an isolated increase in red cells.
• Acquired activating JAK2 mutations occur in approximately 98% of cases: V617F in about 95–97%, and exon 12 variants in most remaining mutation-positive cases. Molecular testing is therefore central to confirmation.
• Low serum erythropoietin (EPO) strongly favors PV over secondary erythrocytosis. An EPO level <2.9 mU/mL was 92% specific but 64% sensitive for PV: a low result is informative, whereas a normal result does not exclude PV.
• Multilineage count elevation adds support. In one cohort, median leukocyte counts were 10.0 versus 7.2 ×10⁹/L and platelet counts 417 versus 191 ×10⁹/L in PV versus secondary erythrocytosis. WBC >8.9 ×10⁹/L and platelets >287 ×10⁹/L had AUCs of 0.79 and 0.90, respectively, but are not stand-alone diagnostic thresholds.

Mechanistic basis

• JAK2 V617F disrupts normal JAK2 autoinhibition; exon 12 variants also activate JAK2. Persistent JAK–STAT, PI3K/AKT, and RAS–ERK signaling drives cytokine hypersensitivity and erythropoietin-independent erythroid growth.
• PV progenitors can form endogenous erythroid colonies without added EPO, directly demonstrating autonomous erythropoiesis.

Bottom line

• PV is overwhelmingly JAK2-associated and produces autonomous erythropoiesis. Low EPO plus leukocytosis and/or thrombocytosis supports PV over secondary erythrocytosis, but confirmation requires JAK2 V617F/exon 12 testing and, when indicated, bone-marrow assessment.